| This subgroup analysis evaluated efficacy and safety outcomes in patients with treatment-resistant depression who relapsed while taking or after discontinuing esketamine nasal spray (ESK) plus an oral antidepressant during SUSTAIN-1 and received a second induction and maintenance treatment with ESK in SUSTAIN-3. |
| Patients with treatment-resistant depression who previously responded to ESK and experienced a relapse benefitted from receiving a second induction and maintenance treatment with ESK. |
| ESK was generally well tolerated and no new safety signals were identified. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.